Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 2464573016 | Rosiglitazone+metformin 2mg/500mg tablet (product) | en | Fully specified name | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 2470936017 | Rosiglitazone+metformin 2mg/500mg tablet | en | Synonym (core metadata concept) | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 2477367012 | Rosiglitazone 2mg / metformin 500mg tablet | en | Synonym (core metadata concept) | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3471170013 | Product containing rosiglitazone 2 mg and metformin 500 mg/1 each oral tablet | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3486681016 | Product containing rosiglitazone 2 mg and metformin 500 mg/1 each oral tablet (clinical drug) | en | Fully specified name | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3501884018 | Rosiglitazone 2 mg and metformin 500 mg oral tablet | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3569836019 | Product containing only rosiglitazone 2 mg and metformin 500 mg/1 each oral tablet | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3569837011 | Product containing only rosiglitazone 2 mg and metformin 500 mg/1 each oral tablet (clinical drug) | en | Fully specified name | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682822017 | Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682823010 | Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682824016 | Metformin hydrochloride 500 mg and rosiglitazone (as rosiglitazone maleate) 2 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3303401000005118 | rosiglitazon + metformin tablet a 2 mg/500 mg | da | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| 3604881000005116 | rosiglitazon + metformin tablet 2 mg/500 mg | da | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| 4712871000005119 | rosiglitazon 2 mg + metformin 500 mg tablet | da | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing metformin and rosiglitazone (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Metformin (substance) | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Rosiglitazone (substance) | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Metformin hydrochloride | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Rosiglitazone maleate | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Metformin-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Rosiglitazone (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | to | false | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Metformin hydrochloride | false | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 500 | false | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Metformin hydrochloride | false | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Metformin hydrochloride | true | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 500 | false | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Rosiglitazone maleate | false | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Rosiglitazone (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | to | false | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing metformin and rosiglitazone in oral dose form (medicinal product form) | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Rosiglitazone maleate | false | Inferred relationship | Some | 1 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Metformin hydrochloride | false | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Metformin and rosiglitazone only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Rosiglitazone maleate | true | Inferred relationship | Some | 2 | |
| Product containing precisely metformin hydrochloride 500 milligram and rosiglitazone (as rosiglitazone maleate) 2 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Metformin hydrochloride | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR